Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy

ABSTRACT: Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy

PROVIDER: PRJNA1057140 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy

Project description:In the phase 3 VOYAGE-1 trial (ClinicalTrials.gov identifier: NCT02207231), guselkumab demonstrated superior efficacy versus placebo and the tumor necrosis factor (TNF)-α antagonist, adalimumab, in patients with moderate-to-severe plaque psoriasis (Blauvelt et al., 2017). Here, skin samples were collected from patients in VOYAGE-1 and pharmacodynamic (PD) responses to guselkumab (vs adalimumab) treatment were assessed over 48 weeks.

2024-07-31 | GSE252029 | GEO

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

Project description:A gene expression profiling study was conducted in which skin biopsy samples were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe psoriasis who participated in the phase 1, guselkumab first-in-human randomized, double-blind, placebo-controlled trial. At week 12, significant reductions in psoriasis gene expression were observed in guselkumab-treated patients. Skin biopsy samples (n=59, LS: lesion, NL: non-lesion) were collected at baseline, weeks 1 and 12 following guselkumab treatment from patients with moderate-to-severe psoriasis for RNA extraction and microarray analysis.

2014-05-14 | E-GEOD-51440 | biostudies-arrayexpress

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

2014-05-14 | GSE51440 | GEO

Transcriptomic analysis of peripheral blood mononuclear cells (PBMC) in psoriasis patients treated with guselkumab

Project description:Psoriasis is a worldwide chronic inflammatory skin disease. The treatment is usually designed according to its severity. In this research, RNA-seq was performed on the peripheral blood mononuclear cells (PBMCs) of 12 patients with psoriasis before and after treatment (4 week) of guselkumab.

2022-04-27 | GSE201397 | GEO

Test Substudy 2

Project description:Test Substudy 2

| PRJNA656863 | ENA

substudy 2 2

Project description:substudy 2 2

| PRJNA656864 | ENA

Investigation of gene expression in biopsies from psoriasis patients before and after adalimumab treatment. Paired biopsies from non-lesional and lesional before treatment start and from psoriatic skin four and 14 days treatment start were included.

Project description:Gene expression in psoriatic skin has not previously been described as early as four days after treatment start. No clinical or histological changes are seen four days after treatment start but few genes have been shown to be regulated that early. We aimed to investigate changes in gene expression in the very early phase after adalimumab treatment. Paired punch biopsies from 10 psoriasis patients were obtained before and four and 14 days after treatment start. RNA was isolated using the Promega SV Total RNA Isolation System (Promega, Madison, USA) and a total of 100 ng RNA was analysed by the Human Gene 1.0 ST Array (Affymetrix, Inc., Santa Clara, CA, USA). All array data processing and analysis were performed in R version 3.1.2 (2014-10-31).

2016-11-21 | E-MTAB-5262 | biostudies-arrayexpress

CARDIA Year 7 Broad Metabolomics Substudy

Project description:CARDIA Year 7 Broad Metabolomics Substudy

| PRJNA1024635 | ENA

A nested case-control study to investigate drivers for metastatic disease in breast cancer (QC substudy)

Project description:This is a quality control (QC) substudy of GSE48091. The QC substudy comprises gene-expression profiling of re-extracted tumor RNA for a subset of the tumours in the full study. As background, a population-based cohort study of metastatic breast cancer patients was first designed. Thereafter, a case-control study nested in the corresponding population-based cohort of primary breast cancer patients was designed by selecting distant metastasis-free controls to each case. Tumor RNA was extracted in the same order. All RNA was profiled on microarrays in randomized order. For quality control, RNA was also re-extracted (new tumor piece) in a randomized order for randomly selected cases-controls sets and profiled with the rest. Keywords: Expression profiling by array The nested case-control study included 768 study subjects corresponding to 623 primary tumor samples. This QC substudy comprises 97 of the study subjects (all different primary tumor samples). Details concerning case-control status are given in the samples section. This Series includes a re-analysis of 97 samples from GSE48091. The file "full_data_matrix.txt" includes the re-normalized values for the 97 samples from GSE48091 and the normalized values for the 97 new samples from the same patients that were analyzed together.

2016-05-28 | E-GEOD-81954 | biostudies-arrayexpress

Molecular and cellular profilling of scalp psoriasis reveals differences and similarities compared to skin psoriasis

Project description:Scalp psoriasis shows a variable clinical spectrum and in many cases poses a great therapeutic challenge. However, it remains unknown whether the immune response of scalp psoriasis differs from understood pathomechanisms of psoriasis on other skin areas. We sought to determine the cellular and mollecular phenotype of scalp psoriasis by performing a comparative analysis of scalp vs skin using lesional and nonlesional samples from 20 Caucasian subjects with untreated moderate to severe psoriasis and significant scalp involvement, and 10 control subjects without psoriasis. Our results suggest that even in the scalp psoriasis is a disease of the inter-follicular skin. The immune mechanisms that mediate scalp psoriasis were found to be similar to those involved in skin psoriasis. However, the magnitude of dysregulation, number of differentially expressed genes, and enrichment of the psoriatic genomic fingerprinting were more prominent in skin lesions. Furthermore, the scalp transcriptome showed increased modulation of several gene-sets, particularly those induced by interferon-gamma, compared with skin psoriasis which was mainly associated with activation of TNFâµ/L-17/IL-22-induced keratinocyte response genes. We also detected differences in expression of gene-sets involving negative regulation, epigenetic regulation, epidermal differentiation, and dendritic cell or Th1/Th17/Th22-related T-cell processes. To define the transcriptomic profile of scalp skin, punch biopsies (6 mm diameter) were obtained from 20 Caucasian patients with untreated moderate to severe psoriasis with significative scalp involvement and 10 control subjects without psoriasis (N). Lesional (LS) samples were isolated from the infiltrated border of a plaque of psoriasis. Non lesional (NL) samples were taken from scalp areas with no visible psoriasis between the infiltrated plaques.

2015-11-25 | E-GEOD-75343 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data